Diabetes company brings European phase III trial forward as US troubles continue
Diamyd Medical has moved up its phase III start date in Europe to avoid potential delays in the patient recruitment process caused by the partial clinical hold in the US, which was implemented by the FDA in September.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
It was a letdown for Diamyd Medical, which is based in Stockholm, when the the US Food and Drug Administration (FDA) last month placed the company's phase III trial under a "partial clinical hold." The FDA said it couldn't approve all parts of the Swedish company's application to begin the study.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
